This review systematically summarizes the key improvements and evolutionary progress in the prime editor design and its updated delivery systems, with a particular focus on innovative modifications that have successfully overcome technical barriers.
Abstract
Prime editing (PE), as a transformative genome-editing technology, overcomes many of the limitations of CRISPR-Cas9, particularly by enabling high-fidelity base conversions independent of double-strand breaks (DSBs). This unique mechanism significantly reduces unintended insertions, deletions, and chromosomal rearrangements, positioning PE as a safer and more precise tool for therapeutic gene correction. Recently, the world's first FDA-approved PE clinical trial (PM359 for chronic granulomatous disease) was officially launched, representing a major milestone in the field and highlighting the growing clinical translational potential of PE for treating human genetic disorders. Since the introduction of PE technology, extensive research efforts have been devoted to improving its gene correction efficiency, expanding the editing window, broadening target-site compatibility, reducing the size of the editing protein, and optimizing in vivo delivery vector systems. This review systematically summarizes the key improvements and evolutionary progress in the prime editor design and its updated delivery systems, with a particular focus on innovative modifications that have successfully overcome technical barriers. This study also highlights recent advances in engineered PE variants and their derivative systems, which have collectively expanded the scope and precision of PE-mediated gene correction. Additionally, this study critically discusses the remaining limitations and challenges associated with its application.
Prime editing has developed into a versatile precision genome editing platform, but the evidence base remains heterogeneous and predominantly preclinical.
This study provides a comprehensive analysis of recent literature on CRISPR-based genome editing, emphasizing next-generation modalities like base editing and prime editing, and their impact on target specificity and genomic integrity.
Abraham E. Ubhenin, F. Adamude, D. O. Ochalefu et al.· Nigerian Medical Journal· 0 citations
Recent advances in CRISPR-Cas9–mediated genome editing are highlighted, emphasizing breakthroughs in primary cell editing and the development of translational models for genetic diseases and diabetes mellitus.
Md Nur Islam, Md. Mahmudul Islam, Han Feng et al.· Molecular Biology Reports· 0 citations
Significant challenges remain for its broad applicability as a potential curative therapy for human genetic diseases, mainly related to ensuring efficient and safe delivery to target tissues.
Emilio M. García-Tenorio, Mar Álvarez, Eva Richard et al.· Methods in molecular biology· 0 citations
This review starts by examining the advantages and limitations of various physical methods for delivering Cas9, and highlights key applications of CRISPR systems in epigenetic modifications, and explores the use of CRISPR-Cas9 technology in genome editing, with a particular focus on base editing and prime editing.
Suhail Ahmad Sheikh, W. Shah, Azka Khan et al.· Journal of Population Therap...· 0 citations
Enforcing physics-based constraints prevents AI models from generating unreliable predictions for complex nonlinear systems in weather, climate, and turbulent flows.
MIT News · Artificial Intelligence· news.mit.eduNov 18, 2026